News

Organ donors are critical to the survival of patients whose organs experience severe damage through trauma and disease. However, on average twenty-one people die per day while waiting for a transplant. As a disease that features lung transplantation as a possible course of treatment, those in the cystic fibrosis patient…

The Food and Drug Administration (FDA) will be evaluating the new drug application (NDA) for Vertex Pharmaceutical’s Orkambi, indicated to treat cystic fibrosis in patients with the F508del mutation on Tuesday, and will make a final decision for approval/disapproval by July 5. The Pulmonary-Allergy Drugs Advisory Committee (PADAC) will be…

CARSTAR Automotive Canada Inc. is encouraging Canadians to promote CARSTAR’s Great Strides™ Walk for Cystic Fibrosis Canada through the social media hashtag #AWorldWithoutCF throughout the month of May. The goal is to raise funds to support research and treatments to address cystic fibrosis (CF). CARSTAR is celebrating its first…

Spyryx Biosciences, Inc. has successfully raised $18 million in Series A venture capital financing, which will be used to develop novel therapies to treat respiratory conditions such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The funding was secured through deals with Canaan Partners, Hatteras Venture Partners and…

Parion Sciences, a biopharmaceutical company developing treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or lungs, recently announced that it has begun enrollment of patients with Cystic Fibrosis (CF) in a phase 2 clinical trial of its experimental therapy…

Molecular genetics information company, Good Start Genetics, Inc. has presented data from research being conducted to improve detection of inherited diseases, including cystic fibrosis (CF). The results of two studies that examined detection rates in patients undergoing in vitro fertilization (IVF) were presented  at the 2015 Annual Clinical and Scientific Meeting…

Advanced Inhalation Therapies Ltd (AIT), an anti-microbial therapeutic company, recently announced that the European Commission, acting on recommendations from the Committee for Orphan Medicinal Products of the European Medicines Agency, has granted orphan medicinal product designation to the firm’s proprietary high dose formulation of nitric oxide (NO), AIT-CF, to address the treatment…

Researchers at the University of Calgary in Canada have recently published in the journal BMC Pulmonary Medicine findings indicating that lung colonization by the bacteria Streptococcus pneumonia is relatively rare in patients with cystic fibrosis (CF) and when present, it apparently does not have an adverse impact…

Last Friday marked the start of national Cystic Fibrosis Awareness Month, when thousands of volunteers across the country will fundraise and advocate for more research to fight the disease. The month-long initiative will be spearheaded by the Cystic Fibrosis Foundation (CFF), which will organize a series of events nationwide. The…

The Mauli Ola Foundation (MOF) will launch its 2015 tour to honor Cystic Fibrosis Awareness Month in May with the first Surf Experience Day (SED) in Waikiki, Hawaii having just kicked off this last weekend on May 2, 2015. Sunny Garcia, the MOF Ambassador, has partnered with Hyatt Regency Waikiki…